Malaria Parasite Ligands And Host Cell Receptors

本年度的成就： 1.今年，我们发现间日疟原虫的入侵需要通过AMA 1附着到红细胞来入侵红细胞，而不涉及PvRON 2。 间日疟原虫AMA 1与红细胞的直接结合定义了一种不依赖RON 2的侵袭途径。 李SK，Low LM，Andersen JF，Yeoh LM，Valenzuela Leon PC，Drew DR，Doehl JSP，Calvo E，米勒LH，Beeson JG，Gunalan K. 美国国家科学院2023年1月3日;120（1）：e2215003120。 2.开发CR 1结合间日疟原虫EBP的证据。 未提交出版。 3. Duffy血型是间日疟原虫（P. vivax）侵入红细胞的关键受体，因此，间日疟原虫感染在Duffy阴性流行率高的撒哈拉以南非洲地区被认为是罕见的。然而，最近，在整个撒哈拉以南非洲疟疾传播地区的达菲阴性非洲人中发现了间日疟原虫感染，提出了关于这些间日疟原虫克隆的分子组成和促进其入侵的红细胞受体的重要问题。在此，我们描述了喀麦隆德昌（500名门诊患者中有177名）发热性达菲阴性非洲人中间日疟原虫感染的异常高的数量，与喀麦隆其他地区的桑楚（400名门诊患者中有2名）和Ky-ossi（101名门诊患者中有2名）相比。在讨论中，我们推测了德昌可能解释居住在那里的达菲阴性个体中异常大量的间日疟原虫感染的可能原因。 “在喀麦隆德昌的大量发热达菲阴性非洲人中检测到间日疟原虫感染。Ghyslaine Bruna Djeunang Dongho，Karthigayan Gunalan，Mariangela L'Episcopia，Giacomo Maria Paganotti，Michela Menegon，Rose Efeutmechh Sangong，Georges Bouting Mayaka，Joseph Fondop，Carlo Severini，Martin Sanou Sobze，Louis H米勒，Gianluca Russo.Am J Trop Med Hyg. 2021年1月12日;104（3）：987-992。doi：10.4269/ajtmh.20-1255。 4. FDA批准在马拉维测试DON治疗疟疾。 5.与普拉卡什·斯里尼瓦桑和帕特里克·达菲合作研制恶性疟原虫疫苗。还没说完呢

Accomplishments during the year: 1. This year we showed that invasion of P. vivax required invasion of red cells by attachment of AMA1 to red cells and does not involve PvRON2. The direct binding of Plasmodium vivax AMA1 to erythrocytes defines a RON2-independent invasion pathway. Lee SK, Low LM, Andersen JF, Yeoh LM, Valenzuela Leon PC, Drew DR, Doehl JSP, Calvo E, Miller LH, Beeson JG, Gunalan K. Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2215003120. 2. Develop the evidence that CR1 binds the P. vivax EBP. Not submitted for publication. 3. The Duffy blood group is a critical receptor for Plasmodium vivax (P. vivax) invasion of red blood cells, and consequently, P. vivax infections were considered rare in sub-Saharan Africa where the prevalence of Duffy-negativity is high. However, recently, P. vivax infections have been found in Duffy-negative Africans throughout the malaria transmission area of sub-Saharan Africa, raising important questions concerning the molecular composition of these P. vivax clones and the red blood cell receptors that facilitate their invasion. Here, we describe an unusually high number of P. vivax infections in febrile Duffy-negative Africans in Dschang, Cameroon (177 of 500 outpatients), as compared with Santchou (two of 400 outpatients) and Ky-ossi (two of 101 outpatients), in other areas in Cameroon. In the discussion, we speculate on the possible reasons why Dschang might account for the unusually large numbers of P. vivax infections in Duffy-negative individuals living there. "Plasmodium vivax Infections Detected in a Large Number of Febrile Duffy-Negative Africans in Dschang, Cameroon. Ghyslaine Bruna Djeunang Dongho, Karthigayan Gunalan, Mariangela L'Episcopia, Giacomo Maria Paganotti, Michela Menegon, Rose Efeutmecheh Sangong, Georges Bouting Mayaka, Joseph Fondop, Carlo Severini, Martin Sanou Sobze, Louis H Miller , Gianluca Russo.Am J Trop Med Hyg. 2021 Jan 12;104(3):987-992. doi: 10.4269/ajtmh.20-1255. 4. Test DON for treatment of malaria in Malawi under FDA approval. 5. Work with Prakash Srinivasan and Patrick Duffy on a vaccine against P. falciparum. Not finished yet.